Methods for synthesizing anticoagulant polysaccharides

Abstract

The present invention includes methods for preparing anticoagulant polysaccharides using several non-naturally occurring, engineered sulfotransferase enzymes that are designed to react with aryl sulfate compounds instead of the natural substrate, PAPS, to facilitate sulfo group transfer to polysaccharide sulfo group acceptors. Suitable aryl sulfate compounds include, but are not limited to, p-nitrophenyl sulfate or 4-nitrocatechol sulfate. Anticoagulant polysaccharides produced by methods of the present invention comprise N—, 3—O—, 6-O-sulfated glucosamine residues and 2-O sulfated hexuronic acid residues, have comparable anticoagulant activity compared to commercially-available anticoagulant polysaccharides, and can be utilized to form truncated anticoagulant polysaccharides having a reduced molecular weight.

We claim: 
     
         1 . An N-, 2-O, 3-O, 6-O sulfated, heparan sulfate (N,2,3,6-HS) product formed by a process comprising the following steps:
 (a) providing a starting polysaccharide mixture comprising N-sulfated heparosan;   (b) combining the starting polysaccharide reaction mixture with a reaction mixture comprising a first sulfo group donor and a first sulfotransferase enzyme selected from the group consisting of a hexuronyl 2-O sulfotransferase enzyme (2OST) enzyme and a glucosaminyl 6-O sulfotransferase enzyme (6OST) enzyme, to form a first sulfated polysaccharide product;   (c) combining the first sulfated polysaccharide product with a reaction mixture comprising a second sulfo group donor and a second sulfotransferase enzyme, wherein the second sulfotransferase enzyme is the enzyme that was not selected in step (b), to form a second sulfated polysaccharide product;   (d) combining the second sulfated polysaccharide product with a reaction mixture comprising a third sulfo group donor and a glucosaminyl 3-O sulfotransferase enzyme (3OST) enzyme, to form the N,2,3,6-HS product;
 wherein the sulfotransferase enzyme in each of steps (b), (c), and (d) is selected from the group consisting of a natural sulfotransferase enzyme and an engineered sulfotransferase enzyme,
 wherein a natural sulfotransferase enzyme has sulfotransferase activity with 3′-phosphoadenosine 5′-phosphosulfate (PAPS) as a sulfo group donor and heparan sulfate as a sulfo group acceptor, and when a natural sulfotransferase enzyme is selected in any of steps (b), (c), or (d), the sulfo group donor is PAPS; 
 wherein an engineered sulfotransferase enzyme has sulfotransferase activity with an aryl sulfate compound as a sulfo group donor and heparan sulfate as a sulfo group acceptor, and when an engineered sulfotransferase enzyme is selected in any of steps (b), (c), or (d), the sulfo group donor is an aryl sulfate compound; and 
 
 wherein at least one of the sulfotransferase enzymes selected in steps (b), (c), and (d) is an engineered sulfotransferase enzyme. 
   
     
     
         2 . The N,2,3,6-HS product of  claim 1 , wherein the first sulfotransferase enzyme is the 2OST enzyme, and the second sulfotransferase enzyme is the 6OST enzyme. 
     
     
         3 . The N,2,3,6-HS product of  claim 2 , wherein the 3OST enzyme is an engineered sulfotransferase enzyme. 
     
     
         4 . The N,2,3,6-HS product of  claim 3 , wherein the third sulfo group donor is selected from the group consisting of p-nitrophenyl sulfate (PNS) and 4-nitrocatechol sulfate (NCS). 
     
     
         5 . The N,2,3,6-HS product of  claim 4 , wherein the 3OST enzyme comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 57, and SEQ ID NO: 58. 
     
     
         6 . The N,2,3,6-HS product of  claim 3 , wherein at least one of the 2OSTenzyme and the 6OST enzyme is an engineered sulfotransferase enzyme. 
     
     
         7 . The N,2,3,6-HS product of  claim 6 , wherein the 6OST enzyme is an engineered sulfotransferase enzyme. 
     
     
         8 . The N,2,3,6-HS product of  claim 7 , wherein the second sulfo group donor is selected from the group consisting of PNS and NCS. 
     
     
         9 . The N,2,3,6-HS product of  claim 8 , wherein the 6OST enzyme comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 59, SEQ ID NO: 60, and SEQ ID NO: 61. 
     
     
         10 . The N,2,3,6-HS product of  claim 6 , wherein the 2OSTenzyme is an engineered sulfotransferase enzyme. 
     
     
         11 . The N,2,3,6-HS product of  claim 10 , wherein the first sulfo group donor is selected from the group consisting of PNS and NCS. 
     
     
         12 . The N,2,3,6-HS product of  claim 11 , wherein the 2OSTenzyme comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 41, and SEQ ID NO: 42. 
     
     
         13 . The N,2,3,6-HS product of  claim 2 , wherein the first sulfotransferase reaction mixture further comprises a glucuronyl C 5 -epimerase enzyme. 
     
     
         14 . The N,2,3,6-HS product of  claim 1 , wherein at least a portion of the glucosamine residues within the N-sulfated heparosan are N-acetylated. 
     
     
         15 . The N,2,3,6-HS product according to  claim 1 , wherein the N,2O,3O,6O-HS product is a heparin product, the heparin product comprising polysaccharides having a sequence motif having the structure of Formula I, below:
                                             wherein X is either a sulfo group or an acetate group and Y is either a sulfo group or a hydroxyl group.   
     
     
         16 . The N,2,3,6-HS product according to  claim 15 , wherein the heparin product has anticoagulant activity and is a polydisperse mixture of polysaccharides having a weight average molecular weight,  M   w , of at least 1,000 Da. 
     
     
         17 . The N,2,3,6-HS product according to  claim 16 , wherein the heparin product is completely free of a sulfated polysaccharide impurity selected from the group consisting of dermatan sulfate, chondroitin sulfate, and keratan sulfate, and combinations thereof. 
     
     
         18 . The N,2,3,6-HS product according to  claim 1 , wherein the heparin product is substantially free of a sulfated polysaccharide impurity selected from the group consisting of dermatan sulfate, chondroitin sulfate, and keratan sulfate, and combinations thereof. 
     
     
         19 . A low-molecular weight (LMWH) N,2,3,6-HS product formed by a process comprising the following steps:
 (a) providing a starting polysaccharide mixture comprising N-sulfated heparosan;   (b) combining the starting polysaccharide reaction mixture with a reaction mixture comprising a first sulfo group donor and a first sulfotransferase enzyme selected from the group consisting of a hexuronyl 2-O sulfotransferase enzyme (2OST) enzyme and a glucosaminyl 6-O sulfotransferase enzyme (6OST) enzyme, to form a first sulfated polysaccharide product;   (c) combining the first sulfated polysaccharide product with a reaction mixture comprising a second sulfo group donor and a second sulfotransferase enzyme, wherein the second sulfotransferase enzyme is the enzyme that was not selected in step (b), to form a second sulfated polysaccharide product;   (d) combining the second sulfated polysaccharide product with a reaction mixture comprising a third sulfo group donor and a glucosaminyl 3-O sulfotransferase enzyme (3OST) enzyme, to form an N,2,3,6-HS product;   (e) providing one or more depolymerization agents, wherein the one or more depolymerization agents are selected from the group consisting of a β-elimination agent, a deamination agent, and an oxidation agent; and   (f) treating the N,2,3,6-HS product with the one or more depolymerization agents for a time sufficient to depolymerize at least some of the polysaccharides within the heparin product, thereby forming the LMWH product;
 wherein the sulfotransferase enzyme in each of steps (b), (c), and (d) is selected from the group consisting of a natural sulfotransferase enzyme and an engineered sulfotransferase enzyme,
 wherein a natural sulfotransferase enzyme has sulfotransferase activity with 3′-phosphoadenosine 5′-phosphosulfate (PAPS) as a sulfo group donor and heparan sulfate as a sulfo group acceptor, and when a natural sulfotransferase enzyme is selected in any of steps (b), (c), or (d), the sulfo group donor is PAPS; 
 wherein an engineered sulfotransferase enzyme has sulfotransferase activity with an aryl sulfate compound as a sulfo group donor and heparan sulfate as a sulfo group acceptor, and when an engineered sulfotransferase enzyme is selected in any of steps (b), (c), or (d), the sulfo group donor is an aryl sulfate compound; and 
 
 wherein at least one of the sulfotransferase enzymes selected in steps (b), (c), and (d) is an engineered sulfotransferase enzyme. 
   
     
     
         20 . The LMWH N,2,3,6-HS product according to  claim 19 , wherein the LMWH N,2,3,6-HS product is substantially free of a sulfated polysaccharide impurity selected from the group consisting of dermatan sulfate, chondroitin sulfate, and keratan sulfate, and combinations thereof.